Trial Profile

A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Feb 2017 According to VM BioPharma media release, clinical safety and tolerability data was published online at the scientific journal, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and will be published in a future print issue of the journal.
17 May 2016 According to a ViroMed media release, the US FDA granted fast track designation to VM202 for the potential treatment of ALS. ViroMed expects the publication of data from this trial in H2 2016.
22 Jan 2016 Status changed from active, no longer recruiting to completed, according to a ViroMed Co. media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com